Virinchi Ltd is asking shareholders to approve loans and related party transactions totaling up to ₹140 crore. The company is seeking approval via postal ballot for transactions with Virinchi Health Care Pvt Ltd and Vivo Bio Tech Limited.

Virinchi Ltd Seeks Shareholder Approval for ₹140 Crore Related Party Transactions

Virinchi Ltd is seeking shareholder approval for several financial transactions involving related entities, with a total proposed limit of up to ₹140 crore. The company is initiating a postal ballot process to obtain consent for these key resolutions.

What just happened

The Board of Directors has proposed three resolutions for shareholder approval: up to ₹50 crore in loans to VHCPL under Section 185, material related party transactions (RPTs) with Virinchi Health Care Pvt Ltd (VHCPL) up to ₹60 crore, and with Vivo Bio Tech Limited up to ₹30 crore.

Why this matters

These transactions represent significant financial commitments to related entities. Shareholders need to approve these to ensure compliance and transparency, especially as the limits for VHCPL and Vivo Bio Tech exceed 10% of Virinchi Ltd's consolidated turnover of ₹284.36 crore for FY 2025-26, which is the company's materiality threshold. The financial health of these related parties, both of which reported losses in FY 2025-26, is a key concern.

The backstory

Virinchi Ltd is involved in IT services and healthcare. The proposed transactions are part of the company's strategy to manage capital within its group. The resolutions address loans to VHCPL and RPTs with both VHCPL and Vivo Bio Tech.

What changes now

Shareholder approval via postal ballot is required for these transactions to proceed. The voting period runs from June 15, 2026, to July 14, 2026. The results will be declared by July 16, 2026.

Risks to watch

Both VHCPL and Vivo Bio Tech reported net losses in FY 2025-26. Investors should monitor the repayment capacity of these entities and the potential impact of these inter-corporate exposures on Virinchi Ltd's liquidity.

Peer comparison

No direct peer comparison is available in the filing for these specific related party transactions.

Context metrics (time-bound)

• Virinchi Health Care Pvt Ltd FY26 Performance: Turnover ₹82.99 crore, PAT ₹(33.26) crore, Net Worth ₹(26.36) crore.
• Vivo Bio Tech Limited FY26 Performance: Turnover ₹52.57 crore, PAT ₹(193.61) crore, Net Worth ₹93.22 crore.
• Virinchi Ltd Consolidated Turnover FY26: ₹284.36 crore.
• Materiality Threshold: 10% of consolidated turnover (approx. ₹28.44 crore).
• Voting Period: June 15, 2026 (9:00 a.m. IST) to July 14, 2026 (5:00 p.m. IST).

What to track next

Investors should track the voting outcome and the subsequent financial performance and repayment by VHCPL and Vivo Bio Tech. Monitoring the impact on Virinchi Ltd's own financial health and liquidity will also be crucial.